Cargando…
Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort'
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group
2016
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891508/ https://www.ncbi.nlm.nih.gov/pubmed/27124338 http://dx.doi.org/10.1038/bjc.2016.70 |
| _version_ | 1782435274488283136 |
|---|---|
| author | Pernot, Simon Bachet, Jean-Baptiste Portal, Alix Taieb, Julien |
| author_facet | Pernot, Simon Bachet, Jean-Baptiste Portal, Alix Taieb, Julien |
| author_sort | Pernot, Simon |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-4891508 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2016 |
| publisher | Nature Publishing Group |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-48915082016-06-10 Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' Pernot, Simon Bachet, Jean-Baptiste Portal, Alix Taieb, Julien Br J Cancer Letter to the Editor Nature Publishing Group 2016-05-24 2016-04-28 /pmc/articles/PMC4891508/ /pubmed/27124338 http://dx.doi.org/10.1038/bjc.2016.70 Text en Copyright © 2016 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/4.0/ This work is licensed under the Creative Commons Attribution-Non-Commercial-Share Alike 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/4.0/ |
| spellingShingle | Letter to the Editor Pernot, Simon Bachet, Jean-Baptiste Portal, Alix Taieb, Julien Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title_full | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title_fullStr | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title_full_unstemmed | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title_short | Reply to the comment on ‘Nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after Folfirinox failure: an AGEO prospective multicentre cohort' |
| title_sort | reply to the comment on ‘nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma after folfirinox failure: an ageo prospective multicentre cohort' |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891508/ https://www.ncbi.nlm.nih.gov/pubmed/27124338 http://dx.doi.org/10.1038/bjc.2016.70 |
| work_keys_str_mv | AT pernotsimon replytothecommentonnabpaclitaxelplusgemcitabineformetastaticpancreaticadenocarcinomaafterfolfirinoxfailureanageoprospectivemulticentrecohort AT bachetjeanbaptiste replytothecommentonnabpaclitaxelplusgemcitabineformetastaticpancreaticadenocarcinomaafterfolfirinoxfailureanageoprospectivemulticentrecohort AT portalalix replytothecommentonnabpaclitaxelplusgemcitabineformetastaticpancreaticadenocarcinomaafterfolfirinoxfailureanageoprospectivemulticentrecohort AT taiebjulien replytothecommentonnabpaclitaxelplusgemcitabineformetastaticpancreaticadenocarcinomaafterfolfirinoxfailureanageoprospectivemulticentrecohort |